Services on Demand
Anais Brasileiros de Dermatologia
Print version ISSN 0365-0596On-line version ISSN 1806-4841
REGGIANI, Viviane et al. Posterior subcapsular cataract in patients with pemphigus and pemphigoid using oral corticosteroid. An. Bras. Dermatol. [online]. 2004, vol.79, n.5, pp.539-545. ISSN 0365-0596. http://dx.doi.org/10.1590/S0365-05962004000500003.
BACKGROUND: Oral corticosteroid is the treatment most used for patients with chronic bullous dermatosis, often at high dosages and over long periods of time. Arterial hypertension, diabetes, osteoporosis, infections and hydro-electrolytic disturbances frequently occur as side effects of this therapy. Posterior subcapsular cataract is rarely mentioned in the literature as a side effect of corticosteroid in patients with bullous diseases. OBJECTIVES: To evaluate the incidence of posterior subcapsular cataract as a side effect of oral corticosteroid. METHODS: A retrospective study: 49 patients with chronic bullous diseases using a corticosteroid were followed-up from 1987 to 1997 at the Bullous Dermatosis Outpatient Care Unit of the Department of Dermatology, UNIFESP - EPM. The patients were regularly submitted to ophthalmologic evaluation in search for cortisone cataract. This evaluation was carried out at the beginning of the treatment and regularly during the use of the corticosteroid. RESULTS: From 1987 to 1997, the incidence of posterior subcapsular cataract as a side effect of oral corticosteroid was 28.57% in these patients. CONCLUSIONS: 1) among 49 patients, 14 (28.57%) presented with cortisone cataract. 2) the period of time of prednisone use up to the appearance of cataract varied from eight months to nine years and three months (average 45.71 months). 3) the maximum dose of oral corticosteroid required for the management of the clinical picture ranged from 60 to 120 mg daily (average of 78.57 mg daily).
Keywords : cataract; Adrenal Cortex Hormones [therapeutic use]; pemphigus; pemphigoid, bullous.